The Alzheimer’s Disease (AD) Biomarker Expert Working Group just published a new paper in Neurobiology of Aging. They recommend that certain AD biomarkers be used for clinical assessments, enrolling study participants, and as an outcome in AD clinical trials.
Biomarkers, Alzheimer’s, and clinical trials can help find AD faster and can lead to more effective treatments for AD.
Really?
The Caregiver’s Voice asked two questions in reference to excerpts from Use Biomarkers in Alzheiemr’s Disease Clinical Trials.